MISSISSAUGA, Ontario, Oct. 14 /PRNewswire-FirstCall/ -- CardioGenics Holdings Inc. , provides an update on its submission to FINRA regarding the change in the company’s name, ticker symbol and CUSIP number.
The company has submitted to FINRA all documentation requested in connection with the name change, and the related changes of the ticker symbol and CUSIP number for the company’s common shares. FINRA is working through its internal implementation process, and until such changes are implemented by FINRA, the company’s common shares will continue to trade under its current symbol, JAGH.
About CardioGenics Holdings Inc.
CardioGenics Holdings Inc. develops technology and products targeting the immunoassay segment of the In-Vitro Diagnostic testing market. It has developed the QL Care Analyzer, a proprietary Point Of Care immuno-analyzer, which will run a number of diagnostic tests under development, the first of which will be a series of cardiovascular diagnostic tests. As part of its core proprietary technology, the Company has also developed a proprietary method for silver coating paramagnetic microspheres (a fundamental platform component of immunoassay equipment), which improve instrument sensitivity to light. The Company’s principal offices are located in Mississauga, Ontario, Canada.
Safe Harbor Statement - Certain statements made herein that are not historical are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995 and may contain forward-looking statements, with words such as “Anticipate, “believe,” “expect,” “future,” “may,” “will,” “should,” “plan,” “projected,” “intend,” and similar expressions to identify forward-looking statements. These statements are based on the Company’s beliefs and the assumptions it made using information currently available to it. Because these statements reflect the Company’s current views concerning future events, these statements involve risks, uncertainties and assumptions. The actual results could differ materially from the results discussed in the forward-looking statements. In any event, undue reliance should not be placed on any forward-looking statements, which apply only as of the date of this press release. Accordingly, reference should be made to the Company’s periodic filings with the Securities and Exchange Commission.
SOURCE CardioGenics Holdings Inc.
CONTACT: Adam Holdsworth of The Investor Relations Group, +1-212-825-3210;
or Media Relations: Mike Graff, +1-212-825-3210, both for CardioGenics
Holdings Inc.